Sintilimab and anlotinib with gemcitabine plus cisplatin in advanced biliary tract cancer: SAGC a randomized phase 2 trial

Journal:

Nature Communications

Published:

2025-07-01

DOI:

10.1038/s41467-025-60119-3

Affiliations:

18

Authors:

20

Go to article

Institutions	Authors	Share
Zhejiang Cancer Hospital (ZJCH), China	7.000000	0.35
Hangzhou Institute of Medicine (HIM), CAS, China	3.333333	0.17
Geneseeq Technology - Nanjing, China	2.000000	0.10
Quzhou People's Hospital, China	1.000000	0.05
Taizhou Hospital of Zhejiang Province, China	1.000000	0.05
Sir Run Run Shaw Hospital (SRRSH), Zhejiang University School of Medicine, China	1.000000	0.05
Innovent Biologics, Inc., China	1.000000	0.05
TCM Hospital Changxing, China	1.000000	0.05
Zhejiang Chinese Medical University (ZCMU), China	1.000000	0.05
The University of Kansas (KU), United States of America (USA)	1.000000	0.05
Wenzhou Medical University (WMU), China	0.666667	0.03

Interested in Oncology and Carcinogenesis?